Atlas Trials

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Clinical trial NCT06433999 · COMPLETED

Trial details

NCT number
NCT06433999
Sponsor
Priovant Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
DermatomyositisDermatomyositis, Adult Type
Start date
2024-08-28
Primary completion
2025-02-28
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.